Janice K. Albrecht

Statistics

Publications

Citations

34.7K

H-Index

Active since

1984

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Johns Hopkins University

Johns Hopkins Medicine

Sorbonne Université

Cornell University

Janice K. Albrecht is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in viral hepatitis, antiviral therapy, and interferon-based therapy.

Publications per year

1984–2016

Publications

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Michael P. Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet · 2001 · 6.1K citations

Medicine, Internal Medicine, Pharmacotherapy +17

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

John G. McHutchison, Stuart C. Gordon, Eugene R. Schiff et al. · New England Journal of Medicine · 1998 · 3.5K citations · Full text

Pharmacy, Pharmacotherapy, Hepatic Pharmacotherapy +16

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Fred Poordad, Jonathan McCone, Bruce R. Bacon et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet · 1998 · 2.3K citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

Gary L. Davis, Luis A. Balart, Eugene R. Schiff et al. · New England Journal of Medicine · 1989 · 1.7K citations

Pharmacy, Internal Medicine, Pharmacotherapy +14

1–5 of 91